Worldwide Esophageal Cancer Collaboration

pathologic staging data

T. W. Rice, L. Q. Chen, W. L. Hofstetter, B. M. Smithers, V. W. Rusch, B. P L Wijnhoven, K. L. Chen, A. R. Davies, X. B. D'Journo, K. A. Kesler, J. D. Luketich, M. K. Ferguson, J. V. Räsänen, R. van Hillegersberg, W. Fang, L. Durand, I. Cecconello, W. H. Allum, R. J. Cerfolio, M. Pera & 18 others S. M. Griffin, R. Burger, J. F. Liu, M. S. Allen, S. Law, T. J. Watson, G. E. Darling, W. J. Scott, A. Duranceau, C. E. Denlinger, P. H. Schipper, T. E M R Lerut, M. B. Orringer, Hemant Ishwaran, C. Apperson-Hansen, L. M. DiPaola, M. E. Semple, E. H. Blackstone

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We report data—simple descriptions of patient characteristics, cancer categories, and non–risk-adjusted survival—for patients with pathologically staged cancer of the esophagus and esophagogastric junction after resection or ablation with no preoperative therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted de-identified data using standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 13,300 patients, 5,631 had squamous cell carcinoma, 7,558 adenocarcinoma, 85 adenosquamous carcinoma, and 26 undifferentiated carcinoma. Patients were older (62 years) men (80%) with normal body mass index (51%), little weight loss (1.8 kg), 0–2 ECOG performance status (83%), and a history of smoking (70%). Cancers were pT1 (24%), pT2 (15%), pT3 (50%), pN0 (52%), pM0 (93%), and pG2-G3 (78%); most involved distal esophagus (71%). Non–risk-adjusted survival for both squamous cell carcinoma and adenocarcinoma was monotonic and distinctive across pTNM. Survival was more distinctive for adenocarcinoma than squamous cell carcinoma when pT was ordered by pN. Survival for pTis-1 adenocarcinoma was better than for squamous cell carcinoma, although monotonic and distinctive for both. WECC pathologic staging data is improved over that of the 7th edition, with more patients studied and patient and cancer variables collected. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics, and should direct 9th edition data collection. However, the role of pure pathologic staging as the principal point of reference for esophageal cancer staging is waning.

Original languageEnglish (US)
Pages (from-to)724-733
Number of pages10
JournalDiseases of the Esophagus
Volume29
Issue number7
DOIs
StatePublished - Oct 1 2016

Fingerprint

Esophageal Neoplasms
Squamous Cell Carcinoma
Adenocarcinoma
Neoplasm Staging
Neoplasms
Survival
Adenosquamous Carcinoma
Risk Adjustment
Esophagogastric Junction
Esophagus
Comorbidity
Weight Loss
Body Mass Index
Smoking
Demography
Carcinoma
Mortality
Therapeutics

Keywords

  • cancer staging
  • decision-making
  • esophagectomy
  • prognostication
  • survival

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Rice, T. W., Chen, L. Q., Hofstetter, W. L., Smithers, B. M., Rusch, V. W., Wijnhoven, B. P. L., ... Blackstone, E. H. (2016). Worldwide Esophageal Cancer Collaboration: pathologic staging data. Diseases of the Esophagus, 29(7), 724-733. https://doi.org/10.1111/dote.12520

Worldwide Esophageal Cancer Collaboration : pathologic staging data. / Rice, T. W.; Chen, L. Q.; Hofstetter, W. L.; Smithers, B. M.; Rusch, V. W.; Wijnhoven, B. P L; Chen, K. L.; Davies, A. R.; D'Journo, X. B.; Kesler, K. A.; Luketich, J. D.; Ferguson, M. K.; Räsänen, J. V.; van Hillegersberg, R.; Fang, W.; Durand, L.; Cecconello, I.; Allum, W. H.; Cerfolio, R. J.; Pera, M.; Griffin, S. M.; Burger, R.; Liu, J. F.; Allen, M. S.; Law, S.; Watson, T. J.; Darling, G. E.; Scott, W. J.; Duranceau, A.; Denlinger, C. E.; Schipper, P. H.; Lerut, T. E M R; Orringer, M. B.; Ishwaran, Hemant; Apperson-Hansen, C.; DiPaola, L. M.; Semple, M. E.; Blackstone, E. H.

In: Diseases of the Esophagus, Vol. 29, No. 7, 01.10.2016, p. 724-733.

Research output: Contribution to journalArticle

Rice, TW, Chen, LQ, Hofstetter, WL, Smithers, BM, Rusch, VW, Wijnhoven, BPL, Chen, KL, Davies, AR, D'Journo, XB, Kesler, KA, Luketich, JD, Ferguson, MK, Räsänen, JV, van Hillegersberg, R, Fang, W, Durand, L, Cecconello, I, Allum, WH, Cerfolio, RJ, Pera, M, Griffin, SM, Burger, R, Liu, JF, Allen, MS, Law, S, Watson, TJ, Darling, GE, Scott, WJ, Duranceau, A, Denlinger, CE, Schipper, PH, Lerut, TEMR, Orringer, MB, Ishwaran, H, Apperson-Hansen, C, DiPaola, LM, Semple, ME & Blackstone, EH 2016, 'Worldwide Esophageal Cancer Collaboration: pathologic staging data', Diseases of the Esophagus, vol. 29, no. 7, pp. 724-733. https://doi.org/10.1111/dote.12520
Rice TW, Chen LQ, Hofstetter WL, Smithers BM, Rusch VW, Wijnhoven BPL et al. Worldwide Esophageal Cancer Collaboration: pathologic staging data. Diseases of the Esophagus. 2016 Oct 1;29(7):724-733. https://doi.org/10.1111/dote.12520
Rice, T. W. ; Chen, L. Q. ; Hofstetter, W. L. ; Smithers, B. M. ; Rusch, V. W. ; Wijnhoven, B. P L ; Chen, K. L. ; Davies, A. R. ; D'Journo, X. B. ; Kesler, K. A. ; Luketich, J. D. ; Ferguson, M. K. ; Räsänen, J. V. ; van Hillegersberg, R. ; Fang, W. ; Durand, L. ; Cecconello, I. ; Allum, W. H. ; Cerfolio, R. J. ; Pera, M. ; Griffin, S. M. ; Burger, R. ; Liu, J. F. ; Allen, M. S. ; Law, S. ; Watson, T. J. ; Darling, G. E. ; Scott, W. J. ; Duranceau, A. ; Denlinger, C. E. ; Schipper, P. H. ; Lerut, T. E M R ; Orringer, M. B. ; Ishwaran, Hemant ; Apperson-Hansen, C. ; DiPaola, L. M. ; Semple, M. E. ; Blackstone, E. H. / Worldwide Esophageal Cancer Collaboration : pathologic staging data. In: Diseases of the Esophagus. 2016 ; Vol. 29, No. 7. pp. 724-733.
@article{64ff090a9c4a42a8b108d88aff5a3d8d,
title = "Worldwide Esophageal Cancer Collaboration: pathologic staging data",
abstract = "We report data—simple descriptions of patient characteristics, cancer categories, and non–risk-adjusted survival—for patients with pathologically staged cancer of the esophagus and esophagogastric junction after resection or ablation with no preoperative therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted de-identified data using standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 13,300 patients, 5,631 had squamous cell carcinoma, 7,558 adenocarcinoma, 85 adenosquamous carcinoma, and 26 undifferentiated carcinoma. Patients were older (62 years) men (80{\%}) with normal body mass index (51{\%}), little weight loss (1.8 kg), 0–2 ECOG performance status (83{\%}), and a history of smoking (70{\%}). Cancers were pT1 (24{\%}), pT2 (15{\%}), pT3 (50{\%}), pN0 (52{\%}), pM0 (93{\%}), and pG2-G3 (78{\%}); most involved distal esophagus (71{\%}). Non–risk-adjusted survival for both squamous cell carcinoma and adenocarcinoma was monotonic and distinctive across pTNM. Survival was more distinctive for adenocarcinoma than squamous cell carcinoma when pT was ordered by pN. Survival for pTis-1 adenocarcinoma was better than for squamous cell carcinoma, although monotonic and distinctive for both. WECC pathologic staging data is improved over that of the 7th edition, with more patients studied and patient and cancer variables collected. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics, and should direct 9th edition data collection. However, the role of pure pathologic staging as the principal point of reference for esophageal cancer staging is waning.",
keywords = "cancer staging, decision-making, esophagectomy, prognostication, survival",
author = "Rice, {T. W.} and Chen, {L. Q.} and Hofstetter, {W. L.} and Smithers, {B. M.} and Rusch, {V. W.} and Wijnhoven, {B. P L} and Chen, {K. L.} and Davies, {A. R.} and D'Journo, {X. B.} and Kesler, {K. A.} and Luketich, {J. D.} and Ferguson, {M. K.} and R{\"a}s{\"a}nen, {J. V.} and {van Hillegersberg}, R. and W. Fang and L. Durand and I. Cecconello and Allum, {W. H.} and Cerfolio, {R. J.} and M. Pera and Griffin, {S. M.} and R. Burger and Liu, {J. F.} and Allen, {M. S.} and S. Law and Watson, {T. J.} and Darling, {G. E.} and Scott, {W. J.} and A. Duranceau and Denlinger, {C. E.} and Schipper, {P. H.} and Lerut, {T. E M R} and Orringer, {M. B.} and Hemant Ishwaran and C. Apperson-Hansen and DiPaola, {L. M.} and Semple, {M. E.} and Blackstone, {E. H.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1111/dote.12520",
language = "English (US)",
volume = "29",
pages = "724--733",
journal = "Diseases of the Esophagus",
issn = "1120-8694",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Worldwide Esophageal Cancer Collaboration

T2 - pathologic staging data

AU - Rice, T. W.

AU - Chen, L. Q.

AU - Hofstetter, W. L.

AU - Smithers, B. M.

AU - Rusch, V. W.

AU - Wijnhoven, B. P L

AU - Chen, K. L.

AU - Davies, A. R.

AU - D'Journo, X. B.

AU - Kesler, K. A.

AU - Luketich, J. D.

AU - Ferguson, M. K.

AU - Räsänen, J. V.

AU - van Hillegersberg, R.

AU - Fang, W.

AU - Durand, L.

AU - Cecconello, I.

AU - Allum, W. H.

AU - Cerfolio, R. J.

AU - Pera, M.

AU - Griffin, S. M.

AU - Burger, R.

AU - Liu, J. F.

AU - Allen, M. S.

AU - Law, S.

AU - Watson, T. J.

AU - Darling, G. E.

AU - Scott, W. J.

AU - Duranceau, A.

AU - Denlinger, C. E.

AU - Schipper, P. H.

AU - Lerut, T. E M R

AU - Orringer, M. B.

AU - Ishwaran, Hemant

AU - Apperson-Hansen, C.

AU - DiPaola, L. M.

AU - Semple, M. E.

AU - Blackstone, E. H.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - We report data—simple descriptions of patient characteristics, cancer categories, and non–risk-adjusted survival—for patients with pathologically staged cancer of the esophagus and esophagogastric junction after resection or ablation with no preoperative therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted de-identified data using standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 13,300 patients, 5,631 had squamous cell carcinoma, 7,558 adenocarcinoma, 85 adenosquamous carcinoma, and 26 undifferentiated carcinoma. Patients were older (62 years) men (80%) with normal body mass index (51%), little weight loss (1.8 kg), 0–2 ECOG performance status (83%), and a history of smoking (70%). Cancers were pT1 (24%), pT2 (15%), pT3 (50%), pN0 (52%), pM0 (93%), and pG2-G3 (78%); most involved distal esophagus (71%). Non–risk-adjusted survival for both squamous cell carcinoma and adenocarcinoma was monotonic and distinctive across pTNM. Survival was more distinctive for adenocarcinoma than squamous cell carcinoma when pT was ordered by pN. Survival for pTis-1 adenocarcinoma was better than for squamous cell carcinoma, although monotonic and distinctive for both. WECC pathologic staging data is improved over that of the 7th edition, with more patients studied and patient and cancer variables collected. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics, and should direct 9th edition data collection. However, the role of pure pathologic staging as the principal point of reference for esophageal cancer staging is waning.

AB - We report data—simple descriptions of patient characteristics, cancer categories, and non–risk-adjusted survival—for patients with pathologically staged cancer of the esophagus and esophagogastric junction after resection or ablation with no preoperative therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted de-identified data using standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 13,300 patients, 5,631 had squamous cell carcinoma, 7,558 adenocarcinoma, 85 adenosquamous carcinoma, and 26 undifferentiated carcinoma. Patients were older (62 years) men (80%) with normal body mass index (51%), little weight loss (1.8 kg), 0–2 ECOG performance status (83%), and a history of smoking (70%). Cancers were pT1 (24%), pT2 (15%), pT3 (50%), pN0 (52%), pM0 (93%), and pG2-G3 (78%); most involved distal esophagus (71%). Non–risk-adjusted survival for both squamous cell carcinoma and adenocarcinoma was monotonic and distinctive across pTNM. Survival was more distinctive for adenocarcinoma than squamous cell carcinoma when pT was ordered by pN. Survival for pTis-1 adenocarcinoma was better than for squamous cell carcinoma, although monotonic and distinctive for both. WECC pathologic staging data is improved over that of the 7th edition, with more patients studied and patient and cancer variables collected. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics, and should direct 9th edition data collection. However, the role of pure pathologic staging as the principal point of reference for esophageal cancer staging is waning.

KW - cancer staging

KW - decision-making

KW - esophagectomy

KW - prognostication

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84991112574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991112574&partnerID=8YFLogxK

U2 - 10.1111/dote.12520

DO - 10.1111/dote.12520

M3 - Article

VL - 29

SP - 724

EP - 733

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

SN - 1120-8694

IS - 7

ER -